Underascertainment of Clinically Meaningful Symptoms During Prostate Cancer Radiation Therapy—Does This Vary by Patient Characteristics?

Sud, Shivani; Gerringer, B.C.; Wacaser, Brandon S.; Tan, Xianming; Tatko, Sarah S.; Royce, Trevor J.; Wang, Andrew Z.; Chen, Ronald C.

doi:10.1016/j.ijrobp.2021.01.034

Cited by 4 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of three randomized studies using three-dimensional conformal radiotherapy (3DCRT) in the PSA era, only RTOG 94-13 identified any significant toxicity increase with PLNRT, isolated to G ≥ 3 GI side effects and G ≥ 3 lymphopenia in the neoadjuvant ADT subgroups [3] , [32] , [33] . A significant concern regarding physician toxicity reporting is susceptibility to underascertainment [34] . Hanlon et al found that despite overall patient satisfaction, those who received PLNRT had decreased bowel functioning satisfaction, increased use of anal pads, worse nocturia and urinary bother [35] .…”

Section: Discussionmentioning

confidence: 99%

The cost of elective nodal coverage in prostate cancer: Late quality of life outcomes and dosimetric analysis with 0, 45 or 54 Gy to the pelvis

Jensen¹,

Jhavar²,

Ha³

et al. 2022

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The cost of elective nodal coverage in prostate cancer: Late quality of life outcomes and dosimetric analysis with 0, 45 or 54 Gy to the pelvis

Jensen¹,

Jhavar²,

Ha³

et al. 2022

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

“…Unlike chemotherapy, recording of radiotherapy toxicity is still inconsistent [13] , [14] . Studies with patients in radiotherapy found, that patients reported symptoms earlier and more frequently than physicians and a higher rate of patient reported clinically meaningful symptoms was found compared to clinician reporting [15] , [16] . In addition to being used in clinical care, PROs are recommended in comparative effectiveness research [17] .…”

Section: Introductionmentioning

confidence: 94%

Feasibility, usability and acceptance of weekly electronic patient-reported outcomes among patients receiving pelvic CT- or online MR-guided radiotherapy – A prospective pilot study

Møller

Pappot

Bernchou

et al. 2022

Technical Innovations & Patient Support in Radiation Oncolo

View full text Add to dashboard Cite

Highlights Recruitment for weekly self-reporting of symptoms in radiotherapy is feasible. The frequency and time spent on responding to 18 symptomatic AEs weekly is feasible. Adherence to weekly self-reporting is high in a population with a sizable proportion of patients age 70 or above. Real-time feedback from clinicians is requested by the patients.

show abstract

“…Of three randomized studies using three-dimensional conformal radiotherapy (3DCRT) in the PSA era, only RTOG 94 − 13 identi ed any signi cant toxicity increase with PLNRT, isolated to G ≥ 3 GI side effects and G ≥ 3 lymphopenia in the neoadjuvant ADT subgroups. (3, 32, 33) A signi cant concern regarding physician toxicity reporting is susceptibility to underascertainment (34). …”

mentioning

confidence: 99%

Prostate or Prostate Fossa Radiotherapy with or Without Dose-Escalated or Conventionally Dosed Pelvic Nodal Radiotherapy: Quality of Life Outcomes and Dosimetric Analysis

Jensen

Jhavar

et al. 2021

Preprint

View full text Add to dashboard Cite

Background We measure the impact of pelvic lymph node radiotherapy (PLNRT) of two doses using conventional fractionation on long term quality of life (QOL) in prostate cancer. Methods Prostate cancer patients recorded baseline scores using the Expanded Prostate Cancer Index Composite (EPIC), prior to definitive or post-prostatectomy radiotherapy. If ENI was given, it was to 45 or 54 Gy. New scores were recorded 20–36 months after radiotherapy. Absolute change in each domain subscale and summary score was recorded as well as if this change met criteria for minimally important difference (MID), with separate multivariate analysis (MVA) for both measures. Subsequent dosimetric analysis was performed. Results Frequency of a MID decline was significantly greater in patients treated with ENI to 54 Gy for urinary function, incontinence, and overall. No urinary decline was correlated with PLNRT to 45 Gy. PLNRT to 54 Gy was significant for decline in urinary function, bother, irritative, incontinence, and overall score in one or both MVA models while 45 Gy was not. Postoperative status was significant for decline in urinary function, incontinence, and overall. Amongst postoperative patients, there was significantly greater decline in urinary function score in the salvage setting. Neither 54 nor 45 Gy significantly affected bowel subscale or overall score decline. Conclusions Using conventional fractionation, adding PLNRT to 54 Gy, but not 45 Gy, correlates with worse urinary QOL, with postoperative patients experiencing a steeper decline. PLNRT had no significant impact on bowel QOL with either dose.

show abstract

Underascertainment of Clinically Meaningful Symptoms During Prostate Cancer Radiation Therapy—Does This Vary by Patient Characteristics?

Cited by 4 publications

References 16 publications

The cost of elective nodal coverage in prostate cancer: Late quality of life outcomes and dosimetric analysis with 0, 45 or 54 Gy to the pelvis

The cost of elective nodal coverage in prostate cancer: Late quality of life outcomes and dosimetric analysis with 0, 45 or 54 Gy to the pelvis

Feasibility, usability and acceptance of weekly electronic patient-reported outcomes among patients receiving pelvic CT- or online MR-guided radiotherapy – A prospective pilot study

Prostate or Prostate Fossa Radiotherapy with or Without Dose-Escalated or Conventionally Dosed Pelvic Nodal Radiotherapy: Quality of Life Outcomes and Dosimetric Analysis

Contact Info

Product

Resources

About